Next Article in Journal
Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review
Next Article in Special Issue
Pharmacogenetics of Anti-Diabetes Drugs
Previous Article in Journal
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Previous Article in Special Issue
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Pharmaceuticals 2010, 3(8), 2554-2567; doi:10.3390/ph3082554
Review

Exenatide Use in the Management of Type 2 Diabetes Mellitus

*  and
Received: 2 July 2010; in revised form: 5 August 2010 / Accepted: 9 August 2010 / Published: 11 August 2010
(This article belongs to the Special Issue Antidiabetic Drugs)
View Full-Text   |   Download PDF [141 KB, uploaded 11 August 2010]
Abstract: Exenatide is a GLP-1 (glucagon-like peptide-1) agonist that has been approved in the UK for use in the management of Type 2 Diabetes Mellitus (T2DM) since 2006. It acts by increasing glucose-induced insulin release and by reducing glucagon secretion postprandially. It therefore increases insulin secretion and reduces glucose levels, especially postprandially. It also reduces gastric emptying and acts centrally to promote satiety. In clinical practice it reduces HbA1c (range; -0.4% to -1.3%), fasting and postprandial blood glucose levels and is the only antidiabetic agent (together with liraglutide; a human GLP-1 analogue) to promote weight loss (range; -1.5 kg to -5.5 kg). It can be used as monotherapy or in combination with metformin and/or sulphonylureas (SU) and/or thiazolinediones (TZD). When compared with insulin it causes similar reductions in HbA1c and glucose levels, but unlike insulin it has the advantage of inducing weight loss. Its main side effect is gastrointestinal (GI) disturbances; nausea is the commonest GI adverse effect, albeit usually mild and transient. Hypoglycaemia is uncommon, especially when used as monotherapy or in combination with metformin. In this review article we scrutinize the currently available evidence for use of exenatide in the management of T2DM.
Keywords: diabetes; exenatide; glycaemic control; incretin mimetics; efficacy; adverse events diabetes; exenatide; glycaemic control; incretin mimetics; efficacy; adverse events
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Kyriacou, A.; Ahmed, A.B. Exenatide Use in the Management of Type 2 Diabetes Mellitus. Pharmaceuticals 2010, 3, 2554-2567.

AMA Style

Kyriacou A, Ahmed AB. Exenatide Use in the Management of Type 2 Diabetes Mellitus. Pharmaceuticals. 2010; 3(8):2554-2567.

Chicago/Turabian Style

Kyriacou, Angelos; Ahmed, Abu Baker. 2010. "Exenatide Use in the Management of Type 2 Diabetes Mellitus." Pharmaceuticals 3, no. 8: 2554-2567.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert